A steadily increasing demand for study participants and the complexities associated with patient enrollment has imposed a significant burden on drug developer companies, prompting them to enlist the services of specialty service providers. Presently, close to 140 companies are actively offering ... Read more

A steadily increasing demand for participants in clinical research studies, coupled to the complexities associated with patient enrolment, have prompted drug / therapy developers to outsource this process to specialty service providers

... Read more

Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of ophthalmic drug developers have demonstrated a preference to outsource ... Read more

Outsourcing has become a popular trend among ophthalmic drug developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages

... Read more

Several big pharma companies are known to outsource more than half of their clinical-stage oligonucleotide manufacturing operations. Anticipating a sharp rise in demand, oligonucleotide manufacturers are increasingly consolidating their portfolios, building new capabilities and expanding their ... Read more

The applications of oligonucleotides are vast, even beyond the life science / pharma sector; however, owing to complexities associated with the synthesis and processing of these molecules, such operations are usually outsourced to capable CMOs

... Read more

The recent surge in the demand of radiopharmaceuticals for diagnostic and therapeutic applications, coupled with the introduction of theranostics, has opened up opportunities for companies having capabilities to manufacture nuclear medicine and radiopharmaceuticals

... Read more